Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

NCT05941507 is registered in ClinicalTrials.gov with LigaChem Biosciences, Inc. as lead sponsor.

NCT NCT05941507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05941507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors
Lead sponsor
LigaChem Biosciences, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 5, 2023
Completion date
May 31, 2027
Enrollment
300 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors